To the Editor:
The clinical picture for SCLC has remained poor for more than 30 years and has continued to be in the research stage. Recently, immune checkpoint inhibitors have changed substantially and revolutionized cancer treatment. The 2017 National Comprehensive Cancer Network (NCCN) guidelines approved nivolumab with or without ipilimumab as subsequent systemic therapy for relapsed or extensive-disease SCLC (ED-SCLC). Nevertheless, the use of nivolumab in the treatment of SCLC has rarely been reported. Stage IV SCLC was clinically diagnosed in a 68year-old Chinese woman without EGFR gene mutation. Gefitinib was prescribed, and she was then treated with two cycles of chemotherapy consisting of etoposide and cisplatin. A review of her computed tomography (CT) images showed progressive disease. The biopsy samples were negative for programmed death ligand 1 (Fig. 1A) ; they were strongly positive for mutL homolog 1, mutS homolog 2, and mutS homolog 6 and diffusely positive for PMS1 homolog 2, mismatch repair system component ( Fig. 1B-E ). Because the CheckMate 025 results indicated that programmed death ligand 1 expression is not Figure 1 . Immunohistopathological analysis demonstrated negative staining for programmed death ligand 1 (PD-L1) and strongly positive staining for mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), and mutS homolog 6 (MSH6) but weakly positive staining for PMS1 homolog 2, mismatch repair system component (PMS2). correlated with the tumor therapeutic response to nivolumab, the patient was then placed on a regimen of nivolumab (200 mg on day 1) every 2 weeks, as arranged after she had given informed consent. She exhibited an excellent partial response to nivolumab after only two doses with minor adverse effects. She was then followed up every 2 weeks and was found to have achieved a partial response (according to a subsequent CT scan after treatment) (Fig. 2 ). The dose regimen was then adjusted to every 4 weeks on account of minor kidney injury that manifested mainly as an increase in creatinine level ( Fig. 3 ). However, despite the fact that according to the NCCN guideline, nivolumab should be used continuously as monotherapy (3 mg/kg every 2 weeks) until progressive disease, follow-up CT scans revealed a sustained partial response. As of March 2018, the patient had remained in clinical remission for 13 months after a total of 10 cycles of nivolumab monotherapy administered in a 12-month period. The outcomes in this case indicate the possibility of using immunotherapy for improving the prognosis and overall survival of patients with SCLC.
To the best of our knowledge, to date there have been 14 reported cases confirming renal side effects associated with programmed death 1 monotherapy (Table 1 ). In general, the clinical symptoms of renal injury are mild, and creatinine level is controlled mainly by low-dose corticosteroids. Hence, cases of gradually increasing serum creatinine level during or after nivolumab monotherapy should be given clinical attention. Because the patient refused to undergo a kidney biopsy, whether her increased serum creatinine level was associated with nivolumab monotherapy remained uncertain.
At present, although nivolumab has been introduced into the NCCN guidelines as second-line treatment for SCLC, the KEYNOTE-028 study and the CheckMate-032 study 1 have reported unsatisfactory response rates. Moreover, the following result of a phase II study was presented in the Ameican Society of Clinical Oncology 2017 convention: pembrolizumab as first-line maintenance therapy after completion chemotherapy did not improve the progression-free survival in patients with ED-SCLC, 2 but significantly prolonged the overall survival, indicating the possibility that the effect of immune drugs is slow but lasting. All these studies have reported unsatisfactory results, perhaps because clinical studies on SCLC are generally small and most are stage II and III clinical trials. 3 In addition, the phase I/III IMPOWER 133 study is currently evaluating the safety and efficacy of atezolizumab by using atezolizumab plus carboplatin/etoposide as the first-line therapy for ED-SCLC. The results are anticipated to provide new therapeutic guidelines for future clinical application.
However, given that the case reported here is only a single case and there was no long-term follow-up, further studies are needed to confirm the efficacy and safety of nivolumab. We owe thanks to the patient and her family. We thank the staff at the Department To the Editor:
The association of agranulocytosis and thymoma is very rare.
Up to now, 20 such cases have been reported, but there have been only five cases of thymoma associated with agranulocytosis and Good syndrome. [1] [2] [3] Agranulocytosis can appear as a first manifestation of thymoma, or it may develop many years after thymectomy. 2 Most of the reported cases have presented with sepsis and other life-threatening infections. Good syndrome was first described in 1954 by Good et al., who reported hypogammaglobulinemia in an adult patient with thymoma. 2 Herein we present the case of a 66-year-old woman who was referred to our hospital in June 2013 because of agranulocytosis and a history of recurrent infections of the upper respiratory tract. Her blood count showed mild anemia (hemoglobin level, 102 g/L), leukopenia (white blood count, 1.1 Â 10 9 /L), and agranulocytosis (neutrophil count, 0.06 Â 10 9 /L). Biochemical analysis showed increased levels of acute-phase proteins and decreased levels of serum immunoglobulins (immunoglobulin G5 level, 1 g/L; immunoglobulin A level, 0.4 g/L; and immunoglobulin M level, 0.1 g/L). Histologic examination of her bone marrow showed hypocellularity (20%-40%), reactive changes with mild fibrosis, and severe hypoplasia of granulocytic lineage without maturation arrest and dysplastic changes. Flow cytometry of the patient's peripheral blood lymphocytes revealed almost undetectable levels of peripheral B cells (0.01% [reference range 3%-13%]), CD4-positive T-cell lymphopenia, and an inverted ratio of CD4-positive cells to CD8-positive cells (0.59 [reference range 1.07-2.77). A chest radiograph showed an enlarged mass in the right side of the mediastinum (Fig. 1) . A computed tomography scan confirmed the presence of a mediastinal mass with a diameter of 13 cm. Complete resection of the tumor mass was performed. Pathohistologic examination showed type AB thymoma (Masaoka stage III, microscopic transcapsular invasion). The patient's postoperative course was complicated by fever, lobar pneumonia, infection of the surgical wound, and a positive Galactomannan test result. Thus, the patient was treated with intensive combined antibiotic and antimycotic therapy, granulocyte colony-stimulating factor, and intravenous immunoglobulins. Three weeks later, her clinical condition improved; however, her severe neutropenia persisted, and cyclosporine A therapy 
